Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and BA.5 mRNA COVID-19 vaccines. Lustig Y, Barda N, Weiss-Ottolenghi Y, Indenbaum V, et al. Vaccine 2024 May 27:S0264-410X(24)00635-2. doi: 10.1016/j.vaccine.2024.

Read + Share

Amedeo Smart

Independent Medical Education

Lustig Y, Barda N, Weiss-Ottolenghi Y, Indenbaum V, et al. Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and BA.5 mRNA COVID-19 vaccines. Vaccine 2024 May 27:S0264-410X(24)00635-2. doi: 10.1016/j.vaccine.2024.
PMID: 38806352